Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona

BMC Medical Genetics

Susana Puig³  Josep Malvehy³  Miquel Ángel Pujana²  Cristina Carrera⁵  Isabel Kolm⁵  Josep Maria Augé⁴  Elisabet Guino²  Nuria Bonifaci²  Joan Anton Puig-Butille³  José Ríos¹  Celia Badenas³  Laura Visa⁵  Zighereda Ogbah⁵ 

[1] Statistics and Methodological Support Unit, Unitat d’Avaluació, Suport i Prevenció (UASP), Hospital Clínic, IDIBAPS, Barcelona, Spain;Bioinformatics and Biostatistics Unit, and Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet, Barcelona, Spain;Centre of Biomedical Research on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain;Melanoma Unit, Biochemistry and Molecular Genetics Service, Hospital Clínic de Barcelona, IDIBAPS, Barcelona University, Barcelona, Spain;Melanoma Unit, Department of Dermatology Hospital Clínic de Barcelona, IDIBAPS, Barcelona University, Barcelona, Spain

关键词: Melanoma;    SNP;    VDR;    Vitamin D;   

Others  :  1177728
DOI  :  10.1186/1471-2350-14-26

 received in 2012-07-23, accepted in 2013-02-12,  发布年份 2013

【 摘 要 】

Background

Serum 25-hydroxyvitamin D3 (Vitamin D) insufficiency and single-nucleotide polymorphisms (SNPs) on its receptor, Vitamin D receptor (VDR), have been reported to be involved in melanoma susceptibility in populations mostly from northern countries.

Objective

To investigate 25-hydroxyvitamin D3 levels and VDR SNPs in melanoma patients from sunny area of Barcelona, two studies were carried out. The first study evaluated the levels of Vitamin D at time of melanoma diagnosis and the second one analyzed the association between VDR genetic variants and risk of having a high nevus number, the strongest phenotypic risk factor for melanoma.

Methods

The levels of 25-hydroxyvitamin D3 in 81 melanoma patients at diagnosis were measured. In a second group of melanoma patients, including 150 with low and 113 with high nevus number, 11 VDR SNPs were analyzed for their association with nevus number.

Results

In the first study, 68% of patients had insufficient levels of 25-hydroxyvitamin D3 (<25 ng/ml). Autumn-winter months and fair phototype were associated with 25-hydroxyvitamin D3 insufficiency; after multivariate analysis, season of sampling remained the only independent predictor of 25-hydroxyvitamin D3 levels. In the second study, VDR variant rs2189480 (P = 0.006) was associated with risk of high nevus number whereas rs2239179 (P = 0.044) and rs7975128 (P = 0.0005) were protective against high nevus number. After Bonferroni adjustment only rs7975128 remained significant. In stratified analysis, SNP rs7975128 was found protective against multiple melanomas (P = 0.021).

Conclusion

This study showed that even in Barcelona, a sunny Mediterranean area, 25-hydroxyvitamin D3 levels were sub-optimal in the majority of melanoma patients at diagnosis. The involvement of VDR in nevi and, in turn, in melanoma susceptibility has also been suggested. Larger studies are needed to confirm our findings.

【 授权许可】

   
2013 Ogbah et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, Holick MF: The role of vitamin D in cancer prevention. Am J Public Health 2006, 96:252-261.
• [2]Borradale D, Kimlin M: Vitamin D in health and disease: an insight into traditional functions and new roles for the ’sunshine vitamin’. Nutr Res Rev 2009, 22:118-136.
• [3]Holick MF: Vitamin D deficiency in 2010: health benefits of vitamin D and sunlight: a D-bate. Nat Rev Endocrinol 2011, 7:73-75.
• [4]Field S, Newton-Bishop JA: Melanoma and vitamin D. Mol Oncol 2011, 5:197-214.
• [5]Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, Chan M, Leake S, Karpavicius B, Haynes S, Kukalizch K, Whitaker L, Jackson S, Gerry E, Nolan C, Bertram C, Marsden J, Elder DE, Barrett JH, Bishop DT: Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009, 27:5439-5444.
• [6]Nurnberg B, Graber S, Gartner B, Geisel J, Pfohler C, Schadendorf D, Tilgen W, Reichrath J: Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res 2009, 29:3669-3674.
• [7]Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: II Sun exposure. Eur J Cancer 2005, 41:45-60.
• [8]Holick MF: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004, 80(Suppl 6):1678S-1688S.
• [9]Holick MF: Vitamin D, deficiency. N Engl J Med 2007, 357:266-281.
• [10]Dusso AS, Brown AJ, Slatopolsky E: Vitamin D. Am J Physiol Renal Physiol 2005, 289:F8-F28.
• [11]Seifert M, Rech M, Meineke V, Tilgen W, Reichrath J: Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. J Steroid Biochem Mol Biol 2004, 89–90:375-379.
• [12]Ranson M, Posen S, Mason RS: Human melanocytes as a target tissue for hormones: in vitro studies with 1 alpha-25, dihydroxyvitamin D3, alpha-Melanocyte stimulating hormone, and beta-Estradiol. J Invest Dermatol 1988, 91:593-598.
• [13]Whitfield GK, Hsieh JC, Jurutka PW, Selznick SH, Haussler CA, MacDonald PN, Haussler MR: Genomic actions of 1,25-dihydroxyvitamin D3. Journal Nutr 1995, 125(Suppl 6):1690S-1694S.
• [14]Nejentsev S, Godfrey L, Snook H, Rance H, Nutland S, Walker NM, Lam AC, Guja C, Ionescu-Tirgoviste C, Undlien DE, Rønningen KS, Tuomilehto-Wolf E, Tuomilehto J, Newport MJ, Clayton DG, Todd JA: Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet 2004, 13:1633-1639.
• [15]Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP: Genetics and biology of vitamin D receptor polymorphisms. Gene 2004, 338:143-156.
• [16]Hutchinson PE, Osborne JE, Lear JT, Smith AG, Bowers PW, Morris PN, Jones PW, York C, Strange RC, Fryer AA: Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000, 6:498-504.
• [17]Halsall JA, Osborne JE, Potter L, Pringle JH, Hutchinson PE: A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma. Br J Cancer 2004, 91:765-770.
• [18]Santonocito C, Capizzi R, Concolino P, Lavieri MM, Paradisi A, Gentileschi S, Torti E, Rutella S, Rocchetti S, Di Carlo A, Di Stasio E, Ameglio F, Zuppi C, Capoluongo E: Association between cutaneous melanoma, breslow thickness and vitamin D receptor BsmI polymorphism. Br J Dermatol 2007, 156:277-282.
• [19]Gapska P, Scott RJ, Serrano-Fernandez P, Mirecka A, Rassoud I, Górski B, Cybulski C, Huzarski T, Byrski T, Nagay L, Maleszka R, Sulikowski M, Lubinski J, Debniak T: Vitamin D receptor variants and the malignant melanoma risk: a population-based study. Cancer Epidemiol 2009, 33:103-107.
• [20]Li C, Liu Z, Wang LE, Gershenwald JE, Lee JE, Prieto VG, Duvic M, Grimm EA, Wei Q: Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case–control study. Int J Cancer 2008, 122:2077-2084.
• [21]Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, Affleck P, Leake S, Haynes S, Karpavicius B, Marsden J, Gerry E, Bale L, Bertram C, Field H, Barth JH, Silva Idos S, Swerdlow A, Kanetsky PA, Barrett JH, Bishop DT, Bishop JA: Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case–control comparisons and a meta-analysis of published VDR data. Eur J Cancer 2009, 45:3271-3281.
• [22]Mocellin S, Nitti D: Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis. Cancer 2008, 113:2398-2407.
• [23]Gandini S, Raimondi S, Gnagnarella P, Dore JF, Maisonneuve P, Testori A: Vitamin D and skin cancer: a meta-analysis. Eur J Cancer 2009, 45:634-641.
• [24]Orlow I, Roy P, Reiner AS, Yoo S, Patel H, Paine S, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Thomas NE, Gruber SB, Anton-Culver H, Rosso S, Gallagher RP, Dwyer T, Kanetsky PA, Busam K, From L, Begg CB, Berwick M, GEM Study Group: Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int J Cancer 2012, 130:405-418.
• [25]Chang YM, Newton-Bishop JA, Bishop DT, Armstrong BK, Bataille V, Bergman W, Berwick M, Bracci PM, Elwood JM, Ernstoff MS, Green AC, Gruis NA, Holly EA, Ingvar C, Kanetsky PA, Karagas MR, Le Marchand L, Mackie RM, Olsson H, Østerlind A, Rebbeck TR, Reich K, Sasieni P, Siskind V, Swerdlow AJ, Titus-Ernstoff L, Zens MS, Ziegler A, Barrett JH: A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer 2009, 124:420-428.
• [26]Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, Melchi CF: Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005, 41:28-44.
• [27]Bishop DT, Demenais F, Iles MM, Harland M, Taylor JC, Corda E, Randerson-Moor J, Aitken JF, Avril MF, Azizi E, Bakker B, Bianchi-Scarrà G, Bressac-de Paillerets B, Calista D, Cannon-Albright LA, Chin-A-Woeng T, Debniak T, Galore-Haskel G, Ghiorzo P, Gut I, Hansson J, Hocevar M, Höiom V, Hopper JL, Ingvar C, Kanetsky PA, Kefford RF, Landi MT, Lang J, Lubiński J: Genome-wide association study identifies three loci associated with melanoma risk. Nature Genet 2009, 41:920-925.
• [28]Falchi M, Bataille V, Hayward NK, Duffy DL, Bishop JA, Pastinen T, Cervino A, Zhao ZZ, Deloukas P, Soranzo N, Elder DE, Barrett JH, Martin NG, Bishop DT, Montgomery GW, Spector TD: Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nature Genet 2009, 41:915-919.
• [29]Barroso E, Fernandez LP, Milne RL, Pita G, Sendagorta E, Floristan U, Feito M, Aviles JA, Martin-Gonzalez M, Arias JI, Zamora P, Blanco M, Lazaro P, Benitez J, Ribas G: Genetic analysis of the vitamin D receptor Gene in two epithelial cancers: melanoma and breast cancer case–control studies. BMC Cancer 2008, 8:385. BioMed Central Full Text
• [30]Aguilera P, Puig S, Guilabert A, Julia M, Romero D, Vicente A, Gonzalez-Ensenat MA, Malvehy J: Prevalence study of nevi in children from Barcelona. Dermoscopy, constitutional and environmental factors. Dermatology 2009, 218:203-214.
• [31]Ersfeld DL, Rao DS, Body JJ, Sackrison JL Jr, Miller AB, Parikh N, Eskridge TL, Polinske A, Olson GT, MacFarlane GD: Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem 2004, 37:867-874.
• [32]de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, Altshuler D: Efficiency and power in genetic association studies. Nature Genet 2005, 37:1217-1223.
• [33]Gonzalez JR, Armengol L, Sole X, Guino E, Mercader JM, Estivill X, Moreno V: SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007, 23:644-645.
• [34]Lips P: Vitamin D physiology. Prog Biophys Mol Biol 2006, 92:4-8.
• [35]Guerrieri-Gonzaga A, Gandini S: Vitamin D and overall mortality. Pigment Cell Melanoma Res 2013, 26:16-28.
• [36]Norman AW, Bouillon R, Whiting SJ, Vieth R, Lips P: 13th Workshop consensus for vitamin D nutritional guidelines. J Steroid Biochem Mol Biol 2007, 103:204-5.
• [37]Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA: The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab 2011, 96:53-8.
• [38]Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S: Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr 2012, 95:91-100.
• [39]Ovesen L, Andersen R, Jakobsen J: Geographical differences in vitamin D status, with particular reference to European countries. Proc Nutr Soc 2003, 62:813-821.
• [40]Vaqueiro M, Bare ML, Anton E, Andreu E, Gimeno C, Group DA: Evaluation assessment of the cut-off point of vitamin D in the population older than 64 years old. Med Clin (Barc) 2006, 127:648-650.
• [41]Mata-Granados JM, Luque de Castro MD, Quesada Gomez JM: Inappropriate serum levels of retinol, alpha-tocopherol, 25 hydroxyvitamin D3 and 24,25 dihydroxyvitamin D3 levels in healthy Spanish adults: simultaneous assessment by HPLC. Clin Biochem 2008, 41:676-680.
• [42]Calatayud M, Jodar E, Sanchez R, Guadalix S, Hawkins F: Prevalence of deficient and insufficient vitamin D levels in a young healthy population. Endocrinol Nutr 2009, 56:164-169.
• [43]González-Molero I, Morcillo S, Valdés S, Pérez-Valero V, Botas P, Delgado E, Hernández D, Olveira G, Rojo G, Gutierrez-Repiso C, Rubio-Martín E, Menéndez E, Soriguer F: Vitamin D deficiency in Spain: a population-based cohort study. Eur J Clin Nutr 2011, 65:321-328.
• [44]Newton-Bishop JA, Chang YM, Elliott F, Chan M, Leake S, Karpavicius B, Haynes S, Fitzgibbon E, Kukalizch K, Randerson-Moor J, Elder DE, Bishop DT, Barrett JH: Relationship between sun exposure and melanoma risk for tumours in different body sites in a large case–control study in a temperate climate. Eur J Cancer 2011, 47:732-741.
• [45]Davies JR, Chang YM, Snowden H, Chan M, Leake S, Karpavicius B, Haynes S, Kukalizch K, Randerson-Moor J, Elliott F, Barth J, Kanetsky PA, Harland M, Bishop DT, Barrett JH, Newton-Bishop JA: The determinants of serum vitamin D levels in participants in a melanoma case–control study living in a temperate climate. Cancer Causes Control 2011, 22:1471-1482.
• [46]Malvy DJ, Guinot C, Preziosi P, Galan P, Chapuy MC, Maamer M, Arnaud S, Meunier PJ, Hercberg S, Tschachler E: Relationship between vitamin D status and skin phototype in general adult population. Photochem Photobiol 2000, 71:466-469.
• [47]Glass D, Lens M, Swaminathan R, Spector TD, Bataille V: Pigmentation and vitamin D metabolism in Caucasians: low vitamin D serum levels in fair skin types in the UK. PLoS One 2009, 4:e6477.
• [48]Springbett P, Buglass S, Young AR: Photoprotection and vitamin D status. J Photochem Photobiol B 2010, 101:160-168.
• [49]Berwick M: The good, the bad, and the ugly of sunscreens. Clin Pharmacol Ther 2011, 89:31-33.
• [50]Kiel DP, Demissie S, Dupuis J, Lunetta KL, Murabito JM, Karasik D: Genome-wide association with bone mass and geometry in the Framingham heart study. BMC Med Genet 2007, 8(Suppl 1):S14. BioMed Central Full Text
• [51]Karami S, Brennan P, Rosenberg PS, Navratilova M, Mates D, Zaridze D, Janout V, Kollarova H, Bencko V, Matveev V, Szeszenia-Dabrowska N, Holcatova I, Yeager M, Chanock S, Menashe I, Rothman N, Chow WH, Boffetta P, Moore LE: Analysis of SNPs and haplotypes in vitamin D pathway genes and renal cancer risk. PLoS One 2009, 4:e7013.
• [52]Bonilla C, Hooker S, Mason T, Bock CH, Kittles RA: Prostate cancer susceptibility loci identified on chromosome 12 in African Americans. PLoS One 2011, 6:e16044.
• [53]Carling T, Rastad J, Akerstrom G, Westin G: Vitamin D receptor (VDR) and parathyroid hormone messenger ribonucleic acid levels correspond to polymorphic VDR alleles in human parathyroid tumors. J Clin Endocrinol Metab 1998, 83:2255-2259.
• [54]Millikan RC, Hummer A, Begg C, Player J, de Cotret AR, Winkel S, Mohrenweiser H, Thomas N, Armstrong B, Kricker A, Marrett LD, Gruber SB, Culver HA, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Busam K, From L, Mujumdar U, Berwick M: Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the genes environment and melanoma study. Carcinogenesis 2006, 27:610-618.